FDA Approves Genglycos for Glycogen Storage Disease Type Ia in Patients 8 and Older
The FDA has granted accelerated approval for Genglycos (pariglasgene brecaparvovec-opnr) as the first treatment for GSDIa in patients aged 8 and older.
Indication
Clinical and regulatory intelligence for Glycogen Storage Disease with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.